Biogen Idec has been unable to shake off Knopp Neurosciences, from which Biogen licensed a compound against Lou Gehrig's disease that fell short in a recent late-stage study.
Biogen Idec ($BIIB) is reaching into its own pocket to make up for a federal tax that hits its gay employees, The Boston Globe reported. Next year the biotech giant is expected to start padding the pay of homosexual staffers who are taxed, unlike their heterosexual coworkers, on health-insurance contributions for their spouses.
Today the company announced the initiative focused on amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, with plans to funnel more than $10 million over three years into projects from neuroscience experts at institutions such as Columbia University, Harvard University, Rockefeller University and Yale University.
In a study sponsored by the ALS Association, researchers have assessed a blood protein biomarker that could be used to track the progression of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Despite falling short of goals in a Phase II trial, Neuraltus Pharmaceuticals saw enough evidence of efficacy in Lou Gehrig's disease patients on its experimental drug to push forward plans for a late-state study. Its decision to start the Phase III program next year underscores the critical need for new therapies against the muscle-disabling disorder.
Researchers from Brigham and Women's Hospital have found a blood biomarker that could detect amyotrophic lateral sclerosis (ALS), a progressive degenerative neurological disease that affects about 30,000 Americans.
Take a piece of paper--folding it makes a paper plane, an envelope, a complex and delicate origami flower, or a screwed-up mess. Take a sequence of amino acids--folding it makes a functional protein,...
A Boston neurologist has won a $1 million prize after identifying a new biomarker for amyotrophic lateral sclerosis and developing a simple gadget that can help researchers track the progression of